SEC Form 4 · accession 0001104659-16-145308
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy A Simonian
Officer — President & CEO · Director
Period of report
Sep 16, 2016
Accepted (ET)
Sep 19, 2016 · 6:59 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.17 | Sep 16, 2016 | A | 75,000 | A | — | Sep 15, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The option becomes exercisable as to 25% of the shares underlying the award on the one year anniversary of the award, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until the fourth anniversary of the date of the award, subject to Dr. Simonian's continued service through each applicable vesting date.